Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10516555 | 0.89 | ALDH1A1 (0.69) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL10515722 | 0.87 | KMT2A (0.51) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL10516434 | 0.87 | CYP3A4 (0.53) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL10669621 | 0.85 | MAPT (0.57) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL25327302 | 0.84 | MAPT (0.72) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL30523094 | 0.84 | MAPT (0.72) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL10515296 | 0.84 | MAPT (0.56) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL10515883 | 0.84 | KDM4E (0.56) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL10516062 | 0.83 | MEN1 (0.52) | MAPTKMT2AKDM4ECYP3A4CYP2C9 | |
| SCHEMBL10517152 | 0.83 | MEN1 (0.52) | MAPTKMT2AKDM4ECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0183169-B1 | HALOGEN-HYDROXY FLAVONE | MERCK PATENT GmbH (DE) | 1989-05-10 | — | — | EP | claimed |
| US-4788215-A | TREATMENT OF HYPERTHYROIDISM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-11-29 | — | — | US | claimed |
| EP-0183169-A2 | Halogen-hydroxy flavone | MERCK PATENT GmbH (DE) | 1986-06-04 | — | — | EP | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-1827407-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | Sirion Therapeutics, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | SYTERA, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007008821-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION | SIRION THERAPEUTICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | SYTERA, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006063128-A2 | METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-0183169-B1 | HALOGEN-HYDROXY FLAVONE | MERCK PATENT GmbH (DE) | 1989-05-10 | — | — | EP | disclosed |
| US-4788215-A | TREATMENT OF HYPERTHYROIDISM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-11-29 | — | — | US | disclosed |
| US-4713465-A | Flavanone intermediates for halogenohydroxyflavones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-12-15 | — | — | US | disclosed |
| EP-0183169-A2 | Halogen-hydroxy flavone | MERCK PATENT GmbH (DE) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135460-A1 | Methods, assays and compositions for treating retinol-related diseases | RBP1, RBP4, TTR | MAPT 223/4885KMT2A 4792/4885KDM4E 4836/4885 |
| US-20070015827-A1 | Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation | RBP1, RBP4, ALDH1A2 | MAPT 1143/4885KMT2A 4397/4885KDM4E 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.